Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AcouSort ABOSTO:ACOU 43 12-1 Month Momentum % is 3.68% as of Aug. 19, 2026. GuruFocus rates OSTO:ACOU with a GF Score™ of 43/100 and a GF Value™ of kr9.17 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,359 Biotechnology companies, AcouSort AB ranks better than 66.52% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-19), AcouSort AB's 12-1 Month Momentum % is 3.68%.
The industry rank for AcouSort AB's 12-1 Month Momentum % or its related term are showing as below:
OSTO:ACOU's 12-1 Month Momentum % is ranked better than 66.52% of 1359
companies
in the Biotechnology industry
Industry Median: -19.95
vs OSTO:ACOU: 3.68
AcouSort AB (OSTO:ACOU) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
AcouSort AB 12-1 Month Momentum % Related Terms
OSTO:ACOU vs VRTX, REGN, RVMD: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, AcouSort AB's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AcouSort AB 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AcouSort AB's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where AcouSort AB's 12-1 Month Momentum % falls into.
AcouSort AB (OSTO:ACOU) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AcouSort AB (OSTO:ACOU) has a 12-1 Month Momentum % of 3.68% as of Aug. 19, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on AcouSort AB and its competitors. According to the industry distribution chart, AcouSort AB ranks #455 out of 1359 companies in the Biotechnology industry, placing it in the top 33.5%.
Is AcouSort AB's 12-1 Month Momentum % too high?
AcouSort AB's current 12-1 Month Momentum % is 3.68%. Based on the distribution chart, AcouSort AB ranks #455 out of 1359 companies in the Biotechnology industry, which is above the industry midpoint. Overall, AcouSort AB has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AcouSort AB's 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, AcouSort AB ranks #455 out of 1359 companies for 12-1 Month Momentum %. This puts AcouSort AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on AcouSort AB and its competitors. AcouSort AB's current 12-1 Month Momentum % is 3.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AcouSort AB stock overvalued right now?
Based on GuruFocus' analysis, AcouSort AB (OSTO:ACOU) is currently considered Possible Value Trap. The stock's GF Value™ is kr9.17, compared to a current price of kr3.16 — trading 65.5% below its estimated fair value. The current 12-1 Month Momentum % is 3.68%. AcouSort AB's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For AcouSort AB (OSTO:ACOU), the current 12-1 Month Momentum % is 3.68% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AcouSort AB (OSTO:ACOU) Overvalued in 2026?
Based on GuruFocus' analysis, AcouSort AB stock appears to be undervalued.
The current stock price of kr3.16 is trading 65.5% below its estimated GF Value™ of kr9.17.
GuruFocus considers AcouSort AB to be Possible Value Trap.
Key valuation signals for OSTO:ACOU:
12-1 Month Momentum %: 3.68%
GF Value™: kr9.17 vs. price of kr3.16 (65.5% below fair value)
No single metric tells the full story. See the OSTO:ACOU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AcouSort AB is a company that specializes in products and solutions for the automated preparation of biological samples for researchers and life science companies. Its technology is based on using ultrasound to isolate, separate, or trap microscopic particles such as blood cells, bacteria, or extracellular vesicles in microfluidic channels. The company's products includes AcouTrap, AcouWash, and AcouPlasma.
43GF Score
Get the complete analysis for OSTO:ACOU
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ACOU has been successfully added to your 
